BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Theratechnologies Inc. (TH.TO) CEO Exits Role as Company Tightens Third-Quarter Loss


10/12/2012 7:14:51 AM

MONTREAL, CANADA--(Marketwire - Oct 11, 2012) - Theratechnologies Inc. (TH.TO)(THER) announced today that John-Michel T. Huss will be leaving his role as President and Chief Executive Officer and as director of the Company, effective immediately.

On an interim basis, Luc Tanguay, Senior Executive Vice President and Chief Financial Officer, will fulfill the duties of President and Chief Executive Officer. Mr. Tanguay has been a member of the management team since 1996 and a member of the Board of Directors since 1993.

"The Board and management thank John for his time with the company and wish him the best of luck in his future endeavours. As a result of his departure, the management team has been tasked to prepare a revised business plan for the Company, which will be communicated to shareholders via conference call by the end of the month," stated Paul Pommier, Chairman of the Board of Directors.

As a result of this announcement, Theratechnologies will not hold its Third Quarter of 2012 Results Conference Call originally scheduled for tomorrow, Friday, October 12, at 8:30 a.m.

About Theratechnologies

Theratechnologies (TH.TO)(THER) is a specialty pharmaceutical company that discovers and develops innovative therapeutic peptide products, with an emphasis on growth-hormone releasing factor peptides. Further information about Theratechnologies is available on the Company''s website at www.theratech.com, on SEDAR at www.sedar.com and on the Securities and Exchange Commission''s website at www.sec.gov.

Forward-Looking Information

This press release contains certain statements that are considered "forward-looking information" within the meaning of applicable securities legislation, which statements may contain such words as "may", "would", "could", "will", "intend", "plan", "anticipate", "believe", "estimate", "expect" and similar expressions. This forward-looking information includes, but is not limited to, information regarding communication to shareholders of a revised business plan by the end of the month.

Forward-looking information is based upon a number of assumptions and is subject to a number of risks and uncertainties, many of which are beyond Theratechnologies'' control that could cause actual results to differ materially from those that are disclosed in or implied by such forward-looking information. These assumptions include, but are not limited to, the fact that no unforeseen event will delay the preparation of the revised business plan and such plan will be accepted by the Board of Directors. These risks and uncertainties include, but are not limited to, the risk that unforeseen events occur and delay the preparation of the revised business plan, or presentation thereof to shareholders by the end of the month, or that the Board of Directors does not approve the proposed revised business plan resulting in a delay in the presentation of such plan to the shareholders.

Theratechnologies refers potential investors to the "Risk Factors" section of its Annual Information Form (AIF) dated February 27, 2012. The AIF is available at www.sedar.com and at www.sec.gov under Theratechnologies'' public filings. The reader is cautioned to consider these and other risks and uncertainties carefully and not to put undue reliance on forward-looking statements. Forward-looking information reflects current expectations regarding future events and speaks only as of the date of this press release and represents Theratechnologies'' expectations as of that date.

Theratechnologies undertakes no obligation to update or revise the information contained in this press release, whether as a result of new information, future events or circumstances or otherwise, except as may be required by applicable law.

Contact:

Roch Landriault

NATIONAL Public Relations

514-843-2345



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES